 Shuttle Pharmaceuticals (NASDAQ: SHPH) is Targeting Massive Multi-Billion-Dollar Markets Through Revolutionary Radiation Therapy Advancements, AI Drug Discovery, and an Ambitious DOGE Mining Expansion! 
Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) is positioning itself as a disruptive force in modern cancer treatment by focusing on technologies designed to enhance radiation therapy effectiveness and improve survival outcomes for patients battling aggressive cancers. Its flagship candidate, Ropidoxuridine (IPdR), is being developed as an orally administered radiation sensitizer for glioblastoma, an area with urgent unmet medical need and limited effective treatment options. Supported by FDA Orphan Drug Designation and strategic collaborations with leading cancer institutions including Georgetown University Medical Center, UNC Medical Center, and Miami Cancer Institute, SHPH is attacking one of the fastest-growing sectors in healthcare as global cancer rates continue to climb. The company’s broader oncology pipeline also includes HDAC inhibitors and advanced diagnostic platforms aimed at driving the future of precision medicine. What separates SHPH from many traditional biotech companies is its willingness to move aggressively into emerging technologies and high-growth sectors. Through its acquisition of Molecule.ai,SHPH gains access to advanced autonomous AI systems capable of accelerating molecular innovation and streamlining therapeutic development. The company is also making a bold push into crypto infrastructure through its planned acquisition of United Dogecoin Inc., a move designed to establish a publicly traded DOGE mining and treasury operation supported by $11 million in PIPE financing and substantial mining capacity. SHPH is crafting a diversified high-upside narrative that continues to attract attention from speculative growth investors searching for breakout opportunities! SHPH is developing into a company not to ignore — now is the time to follow the catalysts, and learn why this emerging growth story is generating serious market attention.
Special Report
How Berkshire’s New York Times Bet Looks TodayAuthored by Leo Miller. Publication Date: 5/14/2026. 
Key Points
- New York Times is the latest addition to the Berkshire portfolio, showing up at the end of 2025.
- New York Times navigated the transition from print to digital media well, now having over 10 million digital subscribers.
- While there are many strong aspects to the New York Times' business, concerning signs exist as well.
- Special Report: Goldman Sachs just told you what to buy (most people missed it)
At the end of 2025, Berkshire Hathaway (NYSE: BRK.B), formerly led by the legendary Warren Buffett, made an interesting portfolio move. The company’s 13F filing revealed that it added a new stock during the quarter, placing a $352 million bet. That stock was The New York Times (NYSE: NYT), a name many likely did not expect. Given that one of the world’s most renowned investment funds has taken a stake in the company, The New York Times is a stock worth examining. Overall, NYT has a lot going for it today, but it also has notable risks worth considering. Understanding The New York Times’ Digital Transformation
The New York Times' business needs little introduction; it is one of the longest-standing and most widely recognized news organizations in the world. However, it is worth understanding how the company has shifted its business in recent years. It is no secret that the traditional print newspaper industry is in structural decline. Notably, from 2021 to 2025, NYT’s print subscribers fell from 795,000 to 570,000. However, the company has been fairly successful in transitioning away from print and toward digital over the past several years. While print subscribers dropped 28% from 2021 to 2025, digital-only subscribers increased 80% from 6.783 million to 12.21 million. Today, digital channels are the dominant force behind NYT’s revenue. Digital subscriptions and digital advertising made up approximately two-thirds of the company’s total revenue over the last 12 months (LTM). Revenue from these streams was approximately $1.92 billion, compared with total revenue of nearly $2.9 billion. While declining, print still represents a significant source of sales. LTM print subscription and print advertising revenue were around $677 million, or 23% of total sales. Other Services revenue accounted for just under 11% of LTM total sales. In this segment, the company licenses its intellectual property, engages in affiliate marketing, and uses excess printing capacity to support third-party distribution needs. Digital and Other Services have been notable growth drivers, offsetting the decline in print. Total Digital revenue rose 70% from 2021 to 2025, and Other Services revenue rose around 43%. This helped total revenue rise 36%. Since the end of 2021, NYT shares are up approximately 70%, modestly ahead of the S&P 500’s 64% return over the same period. Overall, these metrics show that NYT is far from a dead company. Instead, it is evolving with a changing media landscape. The New York Times Wins in Q1NYT’s latest earnings report was strong. Quarterly sales increased 12% year over year (YOY) to $712.2 million, solidly ahead of estimates near $700 million. Notably, adjusted earnings per share (EPS) increased much faster, rising 49% YOY to 61 cents. That was well ahead of estimates of 49 cents, demonstrating significant operating leverage in the business. NYT’s adjusted operating profit (AOP) margin increased by 200 basis points YOY to 16.6%. The firm also reduced its diluted share count by around 0.7% YOY and still has $291.2 million worth of buyback capacity. NYT’s Q2 guidance points to continued growth and margin expansion ahead on a YOY basis. It expects total subscription revenue to rise 9% to 11%, and total advertising revenue to rise by “low double digits.” Meanwhile, NYT projects that adjusted operating costs will rise by just 8% to 9%. The company noted, “We continue to expect 2026 to be another year of healthy growth in revenues and AOP, margin expansion, and strong free cash flow generation." The stock received a meaningful 8% boost after its earnings report. Importantly, the firm’s growth is accelerating rather than tapering off. Last quarter’s 12% growth was the highest since Q4 2022 and a sharp improvement from 7% growth in Q1 2025. Additionally, LTM free cash flow increased by a very healthy 28% YOY to $542 million. News Takes a Backseat: A Concerning IndicatorIn general, the metrics outlined above paint an encouraging picture for NYT. However, there is one key blemish on the company’s recent history. While NYT is best known for news journalism, that is not where the company is growing. At the end of 2025, NYT’s news-only subscribers were just 1.47 million, down 24% YOY. Instead, bundled and other single-product subscriptions are driving growth. Other single products include The Athletic, Audio, Cooking, Games, and Wirecutter. In this category, subscribers rose 24% YOY to 4.27 million. Bundled plans include subscriptions to two or more products and may or may not include a news subscription. Bundled subscribers rose 19% YOY. Thus, interest in what many would consider NYT’s biggest strength — news — appears to be declining, while other products are attracting customers. One reason for this may be the emergence of artificial intelligence (AI). Rather than searching for news on Google and then finding NYT, products like AI Overviews can provide information without requiring readers to open a full article. It is worth questioning whether AI advancements could erode the company’s other product lines over time. New York Times: Berkshire Plants Its Flag in the GroundThere are many strong metrics supporting NYT’s business, which Berkshire likely identified. However, declining interest in news coverage is a crack beneath the surface. In this context, there is significant uncertainty about the stock’s outlook. Taking a bullish stance requires conviction that interest in its non-news products remains strong over the long term, or that demand for news makes a comeback. Berkshire’s investment suggests a belief that one or both of these outcomes will play out. That uncertainty is reflected in the wide range of analyst price targets on NYT. Targets updated after the company’s latest report range as high as $95 and as low as $66. The average of updated targets was around $83, modestly above the MarketBeat consensus target near $81. This updated average implies upside of less than 10%.
This message is a paid advertisement for Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) from Stock News and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Stock News or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) on Interactive Offers' website for additional information about the relationship between Interactive Offers and Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH).
. |
